Skip to main content

Orally-Available Polymers to Treat Alzheimer’s Disease (AD)

Orally-Available Polymers to Treat Alzheimer’s Disease (AD)

Polar Anionic Polymers rescue AD by inhibiting Aβ/PrP

  • Amyloid β-oligomers (Aβ) bind to neurons via Prion Protein (PrP), triggering neurotoxic cascade and Alzheimer’s disease
  • Polar anionic polymers bind to PrP with high affinity, inhibiting Aβ binding
  • Oral delivery of PSCMA (Polymer 3) inhibits the Aβ/PrP interaction and rescues Alzheimer’s Disease-induced learning and memory deficits in mice
  • Pending Patent: US 62/694710
  • Innovators: Stephen M. Strittmatter, M.D., Ph.D. Erik Christian Gunther, Ph.D.